Safety and Effectiveness of an Immunobiological Drug in CoViD-19
Phase 2
- Conditions
- COVID-19 PneumoniaCOVID-19 Respiratory InfectionCovid19
- Interventions
- Drug: Anti-SARS-CoV-2Drug: Placebo
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-09-17
- Target Recruit Count
- 200
- Registration Number
- NCT04913779
- Locations
- 🇦🇷
Hospital General de Agudos Donación Francisco J. Santojanni, Ciudad Autónoma De Buenos Aires, Argentina
© Copyright 2025. All Rights Reserved by MedPath